CLClaudine Lapoumeroulie

Claudine Lapoumeroulie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudine Lapoumeroulie has a total of 349 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cell‐derived microparticles and sickle cell disease chronic vasculopathy in sub‐Saharan Africa: A multinational study

    by Abdoul K. Dembélé, Claudine Lapoumeroulie, Mor Diaw, Oumarou Tessougue, Lucile Offredo, Dapa A. Diallo, Saliou Diop, Jacques Elion, Yves Colin‐Aronovicz, Pierre‐Louis Tharaux, et al.

    Although most individuals with sickle cell disease (SCD) live in sub‐Saharan Africa, the natural history of the disease on this continent remains largely unknown. Intravascular haemolysis results in activation of circulating blood cells and release of microparticles (MPs) that exert pro‐inflammatory effects and contribute to vascular damage. We designed a case‐control study nested in the CADRE cohort (Coeur‐Artère‐DRÉpanocytose, clinical trials.gov identifier NCTO3114137) and based on extreme phenotypes, to analyse blood cell‐derived MPs in 232 adult SS patients at steady state in Bamako and Dakar. Thirty‐six healthy adult controls matched by age and sex were recruited in Bamako. The MPs concentrations were higher in SS patients compared to AA controls with a predominance of erythrocyte‐ and reticulocyte‐derived MPs. These erythroid‐derived MPs were significantly lower in patients with retinopathy (P = 0·022). Reticulocyte‐derived MPs were significantly negatively and positively associated with a history of priapism (P = 0·020) and leg ulcers (P = 0·041) respectively. We describe for the first time the comparative patterns of plasma MPs in healthy subjects and patients with SCD living in sub‐Saharan Africa and exhibiting various complications. Because our present results show no clear pattern of correlation between erythroid MPs and the classical hyper‐haemolytic complications, we hypothesise a weak relevance of the hyper‐haemolysis versus hyper‐viscous paradigm in Africa.


  • Plasma microparticles of sickle patients during crisis or taking hydroxyurea modify endothelium inflammatory properties

    by Yohann Garnier, Séverine Ferdinand, Marie Garnier, Kizzy-Clara Cita, Régine Hierso, Aurélie Claes, Philippe Connes, Marie-Dominique Hardy-Dessources, Claudine Lapouméroulie, Nathalie Lemonne, et al.

    Microparticles (MPs) are submicron extracellular vesicles exposing phosphatidylserine (PS) detected in large quantities in the circulation of sickle cell anemia (SS) patients. Several groups studied the biological effects of MPs generated ex vivo. Here, we analyzed for the first time the impact of circulating MPs of 60 sickle cell disease (SCD) patients on endothelial cells (ECs). (1) SCD MPs were collected cross-sectionally, and compared to MPs isolated from healthy individuals (AA); whereas other plasma MPs were purified in a longitudinal manner, from SS patients (2) before and 2 years after hydroxyurea (HU) treatment onset, or (3) during a vaso-occlusive crisis and at steady state. SS MPs increased EC ICAM-1 mRNA and protein levels, as well as neutrophil adhesion, compared to AA MPs. We showed that ICAM-1 overexpression was mainly caused by MPs derived from erythrocytes, rather than from platelets, and that it was abolished by MPs PS capping using annexin V. MPs from SS patients treated with HU were less potent to induce a pro-inflammatory phenotype in ECs, compared to MPs collected before therapy. In contrast, MPs released during crisis increased ICAM-1 and neutrophil adhesion levels, in a PS-dependent manner, compared to MPs collected at steady state. Furthermore, neutrophil adhesion was abolished by a blocking anti-ICAM-1 antibody. Our study provides evidence that MPs play a key role in SCD pathophysiology by triggering a pro-inflammatory phenotype of endothelial cells. We also uncover a new mode of action for HU and identify potential therapeutics, namely annexin V and anti-ICAM-1 antibodies.


  • Open Access

    New insights into red cell rheology and adhesion in patients with sickle cell anaemia during vaso‐occlusive crises

    by Claudine Lapoumeroulie, Philippe Connes, Sara El Hoss, Regine Hierso, Keyne Charlot, Nathalie Lemonne, Jacques Elion, Caroline Le Van Kim, Marc Romana, Marie‐Dominique Hardy‐Dessources


  • Open Access

    Newborn screening for sickle cell disease in Europe: recommendations from a Pan‐European Consensus Conference

    by Stephan Lobitz, Paul Telfer, Elena Cela, Bichr Allaf, Michael Angastiniotis, Carolina Backman Johansson, Catherine Badens, Celeste Bento, Marelle J. Bouva, Duran Canatan, et al.

    Summary: Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European health care systems. Newborn screening (NBS) forSCDenables early initiation of preventive measures and has contributed to a reduction in childhood mortality fromSCD. Policies and methodologies forNBSvary in different countries, and this might have consequences for the quality of care and clinical outcomes forSCDacross Europe. A two‐day Pan‐European consensus conference was held in Berlin in April 2017 in order to appraise the current status ofNBSforSCDand to develop consensus‐based statements on indications and methodology forNBSforSCDin Europe. More than 50SCDexperts from 13 European countries participated in the conference. This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development ofNBSprogrammes in European countries where they do not yet exist, and to review existing programmes.


  • Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study

    by Valentine Brousse, Sara El Hoss, Naïm Bouazza, Cécile Arnaud, Francoise Bernaudin, Béatrice Pellegrino, Corinne Guitton, Marie‐Hélène Odièvre‐Montanié, David Mames, Chantal Brouzes, et al.

    In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi‐center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ°) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event—acute splenic sequestration (ASS), vaso‐occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death—was used as a composite endpoint. Infants were recruited at a mean age of 4.4 ±1 months. Median follow‐up was 19.4 months.During the study period, 38.6% of infants experienced ≥1 severe event: 14% ASS, 22.8% ≥ 1 VOC (median age: 13.4 and 12.8 months, respectively) and 33.3% required transfusion. Of note, 77% of the cohort was hospitalized, with febrile illness being the leading cause for admission. Univariate analysis of various biomarkers measured at enrollment showed that fetal hemoglobin (HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or ϒ‐globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11‐0.73) and 0.16 (0.06‐0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.


  • A microfluidic approach to study the effect of mechanical stress on erythrocytes in sickle cell disease

    by Maria Alejandra Lizarralde Iragorri, Sara El Hoss, Valentine Brousse, Sophie D. Lefevre, Michael Dussiot, Tieying Xu, Alexander Rodrigo Ferreira, Yann Lamarre, Ana Cristina Silva Pinto, Simone Kashima, et al.

    This work presents a microfluidic device to challenge the deformability of normal and pathological red cells and their resistance to lysis upon mechanical stress.


  • Effects of Poloxamer 188 on red blood cell membrane properties in sickle cell anaemia

    by Barbara Sandor, Mickaël Marin, Claudine Lapoumeroulie, Miklos Rabaï, Sophie D. Lefevre, Nathalie Lemonne, Wassim El Nemer, Anaïs Mozar, Olivier Français, Bruno Le Pioufle, et al.

    Summary: Vaso‐occlusive crisis (VOC) is the main acute complication in sickle cell anaemia (SS) and several clinical trials are investigating different drugs to improve the clinical severity of SS patients. A phase III study is currently exploring the profit of Velopoloxamer in SS during VOCs. We analysed, in‐vitro, the effect of poloxamer (P188) on red blood cell (RBC) properties by investigating haemorheology, mechanical and adhesion functions using ektacytometry, microfluidics and dynamic adhesion approaches, respectively. We show that poloxamer significantly reduces blood viscosity, RBC aggregation and adhesion to endothelial cells, supporting the beneficial use of this molecule in SS therapy.


  • Open Access

    Erythroid Adhesion Molecules in Sickle Cell Anaemia Infants: Insights Into Early Pathophysiology

    by Valentine Brousse, Yves Colin, Catia Pereira, Cecile Arnaud, Marie Helene Odièvre, Anne Boutemy, Corinne Guitton, Mariane de Montalembert, Claudine Lapouméroulie, Julien Picot, et al.


  • Open Access

    Erythroid Adhesion Molecule Expression Profile in Sickle Cell Anemia Infants

    by Valentine Brousse, Yves Colin, Catia Pereira, Arnaud Cecile, Marie-Helene Odievre, Anne Boutemy, Claudine Lapoumeroulie, Julien Picot, Mariane De Montalembert, Caroline Le Van Kim, et al.

    Introduction: In normal conditions, circulating red blood cells (RBCs) are not supposed to adhere. Some erythroid adhesion molecules expressed on young reticulocytes are therefore lost upon maturation. Conversely, abnormal RBC adhesiveness in sickle cell anemia (SCA) through activation, sustained or increased expression of adhesion molecules are considered central in vaso occlusive crisis (VOC), the hallmark of SCA. SCA is seldom symptomatic in the first six months of life. One main explanation lies in the sustained level of fetal hemoglobin (HbF) and F cells during this period preventing HbS polymerization. However, infra clinical vaso occlusion, particularly in the spleen, has been demonstrated to be present and the absolute reticulocyte count is paradoxically elevated in the first semester of life, evidencing the very early onset of hemolysis. Our objectives were to analyze the profile of erythroid adhesion molecules in SCA and non-SCA infants in combination with HbF level, in order to evidence significant differences specifically attributable to SCA, informative on very early pathophysiology and disease severity. Patients and methods: Infants were enrolled in a longitudinal multi center prospective study on prognostic factors in SCA between September 2010 and March 2013. Blood sampling was performed at enrolment (3-6 months) at steady state, in asymptomatic infants. In parallel, blood samples from infants with no hemoglobinopathy were collected. Flow cytometer analysis (BD FACSCanto II) was performed using murine monoclonal antibodies against CD36, CD44, CD47, CD49d, CD58, CD99, CD147, CD239 and CD242. Statistical analysis was performed with Graphpad software, Prism 6. Differences in the percentage of positive cells and the level of expression of molecules between groups were calculated with Mann Whitney test. Results were considered statistically significant at an a-risk level of 5%. Results: Fifty-four SCA infants were included and compared to 17 non-SCA infants. Median age in the two groups was not statistically different (144 days, range 81-196 versus 128, range 68-621, p=0,84). Mean HbF level was, as previously described, statistically increased in SCA compared to non-SCA infants (41.2% +/-11.2 versus 10,4 % +/- 1,8; pDiscussion: Recent publications have pointed to the significance of reticulocytosis associated with an increased risk of death or stroke during childhood. Our results further demonstrate that this early rise of reticulocyte count in SCA infants, despite elevated HbF level, include reticulocytes with a specific adhesion molecule expression profile. This numerically small subpopulation of red cells may play in fact a major role in this complex disease. An interesting hypothesis may be that the spleen, as long as its function is preserved, prevents VOC by trapping this subpopulation in very young infants. As spleen function decreases, proadhesive reticulocytes remain in the circulation, which may, in combination with the decline of HbF, subsequently favor extra splenic VOC. Ongoing analysis will confirm if this idiosyncratic erythroid adhesion molecule profile in infants indeed correlates with HbF level and, importantly, correlates with functional activation, in order to serve as a readily available biomarker of disease severity.

  • Open Access

    Hydroxycarbamide Decreases Sickle Reticulocyte Adhesion to Resting Endothelium by Inhibiting Endothelial Lutheran/Basal Cell Adhesion Molecule (Lu/BCAM) through Phosphodiesterase 4A Activation

    by Vicky Chaar, Sandrine Laurance, Claudine Lapoumeroulie, Sylvie Cochet, Maria De Grandis, Yves Colin, Jacques Elion, Caroline Le Van Kim, Wassim El Nemer